CBUS, a biotechnology company in an unknown sector per available profiles, faces Shariah compliance challenges primarily from elevated debt and liquidity ratios exceeding key thresholds in major screening standards. While non-permissible income remains negligible and core business activities in gene editing and sustainable agriculture align with Islamic principles, financial metrics lead to exclusion from Shariah indices. Purification is required for incidental interest income, estimated at 4.21% of revenue. Investors are advised to monitor debt reduction initiatives for potential compliance improvements.